Mark Pruzanski, CEO & President at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 10,000 shares at $259.47 ($2.6M) on 2014-11-03, disclosed to the SEC on 2014-11-05.
Scheduled sale ($2.6M) by CEO & President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $247.66 | 100 | $25K | 1.0% |
| 2 | $249.69 | 100 | $25K | 1.0% |
| 3 | $250.80 | 384 | $96K | 3.7% |
| 4 | $252.90 | 300 | $76K | 2.9% |
| 5 | $254.29 | 500 | $127K | 4.9% |
| 6 | $255.30 | 300 |
| $77K |
| 3.0% |
| 7 | $256.54 | 200 | $51K | 2.0% |
| 8 | $257.96 | 400 | $103K | 4.0% |
| 9 | $259.47 | 1,100 | $285K | 11.0% |
| 10 | $260.68 | 3,166 | $825K | 31.8% |
| 11 | $261.71 | 2,950 | $772K | 29.8% |
| 12 | $262.46 | 500 | $131K | 5.1% |
| Total | $259.41 avg | 10,000 | $2.6M | 100% |
| Filing → |
| ICPT | SELL | 2019-11-27 | $5.0M | — | Filing → |
| ICPT | SELL | 2018-11-16 | $9.1M | — | Filing → |
| ICPT | BUY | 2018-04-09 | $500K | — | Filing → |